Plasma lipoprotein(a) levels in patients with pulmonary arterial hypertension

Indian Heart Journal

Volumn 53, Issue 1, 2001, Pages 56-60

  Tewari, Satyendra ^a   Gupta, Deepak ^a   Kumar, Sudeep ^a   Garg, Naveen ^a   Godbole, Madan M ^a   Sinha, Nakul ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Lipoproteins; Pulmonary hypertension; Thrombosis

Indexed keywords

LIPOPROTEIN A;

ADULT; ARTICLE; BLOOD; ECHOGRAPHY; EISENMENGER COMPLEX; FEMALE; HUMAN; MALE; PULMONARY HYPERTENSION;

ADULT; EISENMENGER COMPLEX; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LIPOPROTEIN(A); MALE;

EID: 0035222931     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Eaton DL, Fless GM, Ohr WJ, Mcleon JW, Xu QT, Miller CG, et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228
2. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. DNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 300: 132-137
3. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 39: 303-315
4. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989; 339: 301-303
5. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma Lp(a) concentrations. J Clin Invest 1992; 90: 52-60
6. Berg K. Lipoprotein(a): an overview. Chem Phys Lipids 1994; 67: 9-16
7. Esinberg PR, Rich S, Kaufmann L. Evidence for increased thrombin activity in patients with primary pulmonary hypertension (Abstr). Circulation 1987; 76(Suppl IV): IV-1246
8. Fustur V, Steele PM, Edwards WD, Girsh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-585
9. Ryan US. The endothelial surface and response to injury. Fed Proc 1986; 45: 101-108
10. Rabinovitch M, Andrew M, Thorn H, Truder GA, Williams WG, Rowe RD, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76: 1043-1052
11. Hoeper MM, Sosada M, Fabel H. Plasma Coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12: 1446-1449
12. Inglesby TV, Singer JW, Gordon DS. Abnormal fibrinolysis in familial pulmonary hypertension. Am J Medicine 1973; 55: 5-14
13. Framx RC, Zindy F, Coetzee WJ, Hugo N. Possible causal relationship between defective fibrinolysis and pulmonary hypertension. S Afr Med J 1979; 55: 170-173
14. Tubbs RR, Levin RD, Shirey EK, Hoffman GC. Fibrinolysis in familial pulmonary hypertension. Am J Clin Pathol 1979; 71: 384-387
15. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease. Long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76: 1037-1042
16. Vasisht S, Agarwal DP, Wasir HS, Srivastava LM. Lipoportein(a) levels in alcohol drinking and alcohol non-drinking coronary artery disease patients. Indian J Clin Biochem 1996; 11: 176-179
17. Ignastescu M, Kostner K, Zorng, Kneuss IM, Maurer G, Lang IM, et al. Plasma Lp(a) levels are increased in patients with chronic thromboembolic hypertension. Thromb Haemost 1998; 80: 231-232
18. Rader DJ, Brewer HBJ. Lipoprotein(a), clinical approach to a unique atherogenic lipoprotein. JAMA 1992; 267: 1109-1112
19. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-382
20. Berg K, Dahlen G, Frick NH. Lp(a) lipoprotein and pre-Beta lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-235
21. Vashisht S, Wasir HS, Srivastava LM. Association between incidence of lipoprotein(a) positivity and coronary artery disease. Indian Heart J 1992; 44: 223-226
22. Gambhir JK, Gambhir DS, Gaubatz J, Morisett JD. Lipoprotien(a) levels in normal Indian subjects and patients with coronary artery disease (Abstr). Indian Heart J 1998; 50: 653
23. Isser HS, Puri VK, Narain VS, Saran RK, Dwivedi SK, Singh S. Lipoprolein(a) and lipid profile in young patients of myocardial infarction and their first degree relatives (Abstr). Indian Heart J 1998; 50: 626
24. Singh S, Dwivedi SK, Melkani GC, Rani C, Gaur SPS, Mandal SK, et al. Lipoprotein(a) and coronary heart disease in Indian population. J Assoc Phys India 1999; 47: 1157-1160
25. Mohan V, Deepa R, Harnath SP, Premlata G, Rema M, Sastry NG, et al. Lipoprotein(a) is an independent risk factor for coronary artery disease in NIIDM patients in South India. Diabetes Care 1998; 21: 1819-1825
26. Gupta R, Vashisht S, Bahl VK, Wasir HS. Correlation of Lipoprotein(a) to angiographically defined coronary artery disease in Indians. Int J Cardiol 1996; 57: 265-270
27. Vashisht S, Gulati R, Srivastava LM, Narang R, Chopra V, Srivastava N, et al. Apolipoprotein(a) polymorphism and its association with plasma lipoprotein(a) levels: A North India Study. Indian Heart J 2000; 52: 165-170
28. Jose JV, Selvakumar D, Selvakumar, Kangasababapathy. Serum lipoprotein(a) levels in ischemic heart disease. J Assoc Phys India 1997; 45: 766-768
29. Gambhir JK, Kaur H, Gambhir DS, Prabhu KM. Lipoprotein(a) as an independent risk factor for coronary artery disease in patients below 40 years of age. Indian Heart J 2000; 52: 411-415
30. Sandholzer C, Halman DM, Saha N, Sigurdsson G, Csaszar A. Effect of apolipoprotein(a) polymorphism on the lipoprotein(a) concentration in seven ethnic group. Hum Genet 1991; 86: 607-614
31. Enas EA, Dhawan J, Pelkar S. Coronary artery disease in Asian Indians: Lessons learnt and the role of Lipoprotein(a). Indian Heart J 1997; 49: 25-34
32. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117
33. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension from physiology to molecular mechanisms. In: Rubin LJ, Rich S, eds. Primary pulmonary hypertension. New York, Marcel Dekker 1997; 83: 133
34. Rich S. Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary hypertension. N Engl J Med 1992; 327: 76-81
35. Yamaki S, Horiuchi T, Miura M, Suzuki Y, Ishizawa E, Takahashi T. Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension. Chest 1986; 5: 694-998
36. Rich S, Brundage BH. Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cardiol 1989; 14: 545-550
37. Igarashi Y, Yamaura M, Ito M, Inizuka H, Ojima K, Aizawa Y. Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: A transesophageal echocardiographic study. Am Heart J 1998; 136: 965-971
38. Santos R, Foronda A, Foronda G, Maranthao R. Lipoprotein(a) levels are increased in patients with pulmonary artery hypertension (Abstr). Eur Heart J 1998; 3007